Skip to main content
Erschienen in: Current Gastroenterology Reports 6/2010

01.12.2010

Association of Long-Term Proton Pump Inhibitor Therapy with Bone Fractures and Effects on Absorption of Calcium, Vitamin B12, Iron, and Magnesium

verfasst von: Tetsuhide Ito, Robert T. Jensen

Erschienen in: Current Gastroenterology Reports | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

Proton pump inhibitors (PPI) are one of the most widely used classes of drugs. PPIs have a very favorable safety profile, and it is unusual for a patient to stop them because of side effects. However, with increasing numbers of patients chronically taking PPIs for gastroesophageal reflux disease and other common, persistent conditions, the long-term potential adverse effects are receiving increasing attention. An insufficiently studied area receiving much attention is the long-term effect of chronic acid suppression on the absorption of vitamins and nutrients. This increased attention results from the reported potential adverse effect of chronic PPI treatment leading to an increased occurrence of bone fractures. Interest in this area has led to examination of the effects of PPIs on calcium absorption/metabolism and numerous cohort, case-control, and prospective studies of their ability to affect bone density and cause bone fractures. In this article, these studies are systematically examined, as are studies of the effects of chronic PPI use on absorption of VB12, iron, and magnesium. Studies in each area have led to differing conclusions, but when examined systematically, consistent results of several studies support the conclusion that long-term adverse effects on these processes can have important clinical implications.
Literatur
1.
Zurück zum Zitat Lahner E, Annibale B, Delle Fave G: Systematic review: impaired drug absorption related to the co-administration of antisecretory therapy. Aliment Pharmacol Ther 2009, 29:1219–1229.CrossRefPubMed Lahner E, Annibale B, Delle Fave G: Systematic review: impaired drug absorption related to the co-administration of antisecretory therapy. Aliment Pharmacol Ther 2009, 29:1219–1229.CrossRefPubMed
2.
Zurück zum Zitat Jensen RT: Consequences of long-term proton pump blockade: Highlighting insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol 2006, 98:4–19.CrossRefPubMed Jensen RT: Consequences of long-term proton pump blockade: Highlighting insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol 2006, 98:4–19.CrossRefPubMed
3.
Zurück zum Zitat McColl KE: Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol 2009, 104(Suppl 2):S5–S9.CrossRefPubMed McColl KE: Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol 2009, 104(Suppl 2):S5–S9.CrossRefPubMed
4.
Zurück zum Zitat • Lodato F, Azzaroli F, Turco L, et al.: Adverse effects of proton pump inhibitors. Best Pract Res Clin Gastroenterol 2010, 24:193–201. This article is a recent general review of all adverse effects of PPIs, including the absorption of vitamins and nutrients and possible effects on bone fractures. • Lodato F, Azzaroli F, Turco L, et al.: Adverse effects of proton pump inhibitors. Best Pract Res Clin Gastroenterol 2010, 24:193–201. This article is a recent general review of all adverse effects of PPIs, including the absorption of vitamins and nutrients and possible effects on bone fractures.
5.
Zurück zum Zitat Moayyedi P, Cranney A: Hip fracture and proton pump inhibitor therapy: balancing the evidence for benefit and harm. Am J Gastroenterol 2008, 103:2428–2431.CrossRefPubMed Moayyedi P, Cranney A: Hip fracture and proton pump inhibitor therapy: balancing the evidence for benefit and harm. Am J Gastroenterol 2008, 103:2428–2431.CrossRefPubMed
6.
Zurück zum Zitat Yang YX, Lewis JD, Epstein S, Metz DC: Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006, 296:2947–2953.CrossRefPubMed Yang YX, Lewis JD, Epstein S, Metz DC: Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006, 296:2947–2953.CrossRefPubMed
7.
Zurück zum Zitat Ali T, Roberts DN, Tierney WM: Long-term safety concerns with proton pump inhibitors. Am J Med 2009, 122:896–903.CrossRefPubMed Ali T, Roberts DN, Tierney WM: Long-term safety concerns with proton pump inhibitors. Am J Med 2009, 122:896–903.CrossRefPubMed
8.
Zurück zum Zitat Thomson AB, Sauve MD, Kassam N, Kamitakahara H: Safety of the long-term use of proton pump inhibitors. World J Gastroenterol 2010, 16:2323–2330.CrossRefPubMed Thomson AB, Sauve MD, Kassam N, Kamitakahara H: Safety of the long-term use of proton pump inhibitors. World J Gastroenterol 2010, 16:2323–2330.CrossRefPubMed
9.
Zurück zum Zitat Studies link PPIs to increased risk of bacterial infection, bone fracture. Today in Medicine May 21, 2010:1–4. Studies link PPIs to increased risk of bacterial infection, bone fracture. Today in Medicine May 21, 2010:1–4.
10.
Zurück zum Zitat Targownik LE: Another bad break for proton-pump inhibitors? Nat Rev Rheumatol 2009, 5:478–480.CrossRefPubMed Targownik LE: Another bad break for proton-pump inhibitors? Nat Rev Rheumatol 2009, 5:478–480.CrossRefPubMed
11.
Zurück zum Zitat Kirkpantur A, Altun B, Arici M, Turgan C: Proton pump inhibitor omeprazole use is associated with low bone mineral density in maintenance haemodialysis patients. Int J Clin Pract 2009, 63:261–268.CrossRefPubMed Kirkpantur A, Altun B, Arici M, Turgan C: Proton pump inhibitor omeprazole use is associated with low bone mineral density in maintenance haemodialysis patients. Int J Clin Pract 2009, 63:261–268.CrossRefPubMed
12.
Zurück zum Zitat Targownik LE, Lix LM, Leung S, Leslie WD: Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010, 138:896–904.CrossRefPubMed Targownik LE, Lix LM, Leung S, Leslie WD: Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010, 138:896–904.CrossRefPubMed
13.
Zurück zum Zitat Insogna KL: The effect of proton pump-inhibiting drugs on mineral metabolism. Am J Gastroenterol 2009, 104(Suppl 2):S2–S4.CrossRefPubMed Insogna KL: The effect of proton pump-inhibiting drugs on mineral metabolism. Am J Gastroenterol 2009, 104(Suppl 2):S2–S4.CrossRefPubMed
14.
Zurück zum Zitat •• Gray SL, LaCroix AZ, Larson J, et al.: Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med 2010, 170:765–771. This article describes a recent prospective study demonstrating that PPI use is associated with increased occurrence of bone fractures. •• Gray SL, LaCroix AZ, Larson J, et al.: Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med 2010, 170:765–771. This article describes a recent prospective study demonstrating that PPI use is associated with increased occurrence of bone fractures.
15.
Zurück zum Zitat Kaye JA, Jick H: Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008, 28:951–959.CrossRefPubMed Kaye JA, Jick H: Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008, 28:951–959.CrossRefPubMed
16.
Zurück zum Zitat den Elzen WP, Groeneveld Y, de Ruijter W, et al.: Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther 2008, 27:491–497.CrossRef den Elzen WP, Groeneveld Y, de Ruijter W, et al.: Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther 2008, 27:491–497.CrossRef
17.
Zurück zum Zitat Valuck RJ, Ruscin JM: A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004, 57:422–428.CrossRefPubMed Valuck RJ, Ruscin JM: A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004, 57:422–428.CrossRefPubMed
18.
Zurück zum Zitat Termanini B, Gibril F, Sutliff VE III, et al.: Effect of long-term gastric acid suppressive therapy on serum vitamin B 12 levels in patients with Zollinger-Ellison syndrome. Am J Med 1998, 104:422–430.CrossRefPubMed Termanini B, Gibril F, Sutliff VE III, et al.: Effect of long-term gastric acid suppressive therapy on serum vitamin B 12 levels in patients with Zollinger-Ellison syndrome. Am J Med 1998, 104:422–430.CrossRefPubMed
19.
Zurück zum Zitat Nand S, Tanvetyanon T: Proton pump inhibitors and iron deficiency: is the connection real? South Med J 2004, 97:799.CrossRefPubMed Nand S, Tanvetyanon T: Proton pump inhibitors and iron deficiency: is the connection real? South Med J 2004, 97:799.CrossRefPubMed
20.
Zurück zum Zitat Sharma VR, Brannon MA, Carloss EA: Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South Med J 2004, 97:887–889.CrossRefPubMed Sharma VR, Brannon MA, Carloss EA: Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South Med J 2004, 97:887–889.CrossRefPubMed
21.
Zurück zum Zitat Stewart CA, Termanini B, Sutliff VE, et al.: Assessment of the risk of iron malabsorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther 1998, 12:83–98.CrossRefPubMed Stewart CA, Termanini B, Sutliff VE, et al.: Assessment of the risk of iron malabsorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther 1998, 12:83–98.CrossRefPubMed
22.
Zurück zum Zitat Festen HP: Intrinsic factor secretion and cobalamin absorption. Physiology and pathophysiology in the gastrointestinal tract. Scand J Gastroenterol 1991, 26:1–7.CrossRef Festen HP: Intrinsic factor secretion and cobalamin absorption. Physiology and pathophysiology in the gastrointestinal tract. Scand J Gastroenterol 1991, 26:1–7.CrossRef
23.
Zurück zum Zitat Dutta SK: Editorial: vitamin B 12 malabsorption and omeprazole therapy. J Am Coll Nutr 1994, 13:544–545.PubMed Dutta SK: Editorial: vitamin B 12 malabsorption and omeprazole therapy. J Am Coll Nutr 1994, 13:544–545.PubMed
24.
Zurück zum Zitat Koop H: Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole. Aliment Pharmacol Ther 1992, 6:399–406.CrossRefPubMed Koop H: Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole. Aliment Pharmacol Ther 1992, 6:399–406.CrossRefPubMed
25.
Zurück zum Zitat Steinberg WM, King CE, Toskes PP: Malabsorption of protein-bound cobalamin but not unbound cobalamin during cimetidine administration. Dig Dis Sci 1980, 25:188–191.CrossRefPubMed Steinberg WM, King CE, Toskes PP: Malabsorption of protein-bound cobalamin but not unbound cobalamin during cimetidine administration. Dig Dis Sci 1980, 25:188–191.CrossRefPubMed
26.
Zurück zum Zitat • Rozgony NR, Fang C, Kuczmarski MF, Bob H: Vitamin B(12) deficiency is linked with long-term use of proton pump inhibitors in institutionalized older adults: could a cyanocobalamin nasal spray be beneficial? J Nutr Elder 2010, 29:87–99. A recent prospective study demonstrated a marked increase of VB 12 deficiency in elderly institutionalized participants using chronic PPIs and demonstrated the effectiveness of a VB 12 nasal spray. • Rozgony NR, Fang C, Kuczmarski MF, Bob H: Vitamin B(12) deficiency is linked with long-term use of proton pump inhibitors in institutionalized older adults: could a cyanocobalamin nasal spray be beneficial? J Nutr Elder 2010, 29:87–99. A recent prospective study demonstrated a marked increase of VB 12 deficiency in elderly institutionalized participants using chronic PPIs and demonstrated the effectiveness of a VB 12 nasal spray.
27.
Zurück zum Zitat Dharmarajan TS, Kanagala MR, Murakonda P, et al.: Do acid-lowering agents affect vitamin B12 status in older adults? J Am Med Dir Assoc 2008, 9:162–167.CrossRefPubMed Dharmarajan TS, Kanagala MR, Murakonda P, et al.: Do acid-lowering agents affect vitamin B12 status in older adults? J Am Med Dir Assoc 2008, 9:162–167.CrossRefPubMed
28.
Zurück zum Zitat Hirschowitz BI, Worthington J, Mohnen J: Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2008, 27:1110–1121.CrossRefPubMed Hirschowitz BI, Worthington J, Mohnen J: Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2008, 27:1110–1121.CrossRefPubMed
29.
Zurück zum Zitat Norton JA, Fraker DL, Alexander HR, et al.: Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999, 341:635–644.CrossRefPubMed Norton JA, Fraker DL, Alexander HR, et al.: Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999, 341:635–644.CrossRefPubMed
30.
Zurück zum Zitat Gibril F, Jensen RT: Zollinger-Ellison syndrome revisited: diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion. Curr Gastroenterol Rep 2004, 6:454–463.CrossRefPubMed Gibril F, Jensen RT: Zollinger-Ellison syndrome revisited: diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion. Curr Gastroenterol Rep 2004, 6:454–463.CrossRefPubMed
31.
Zurück zum Zitat Metz DC, Jensen RT: Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008, 135:1469–1492.CrossRefPubMed Metz DC, Jensen RT: Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008, 135:1469–1492.CrossRefPubMed
32.
Zurück zum Zitat Force RW, Meeker AD, Cady PS, et al.: Ambulatory care increased vitamin B12 requirement associated with chronic acid suppression therapy. Ann Pharmacother 2003, 37:490–493.CrossRefPubMed Force RW, Meeker AD, Cady PS, et al.: Ambulatory care increased vitamin B12 requirement associated with chronic acid suppression therapy. Ann Pharmacother 2003, 37:490–493.CrossRefPubMed
33.
Zurück zum Zitat Vestergaard P, Rejnmark L, Mosekilde L: Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006, 79:76–83.CrossRefPubMed Vestergaard P, Rejnmark L, Mosekilde L: Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006, 79:76–83.CrossRefPubMed
34.
Zurück zum Zitat Chonan O, Takahashi R, Yasui H, Watanuki M: Effect of L-lactic acid on calcium absorption in rats fed omeprazole. J Nutr Sci Vitaminol (Tokyo) 1998, 44:473–481. Chonan O, Takahashi R, Yasui H, Watanuki M: Effect of L-lactic acid on calcium absorption in rats fed omeprazole. J Nutr Sci Vitaminol (Tokyo) 1998, 44:473–481.
35.
Zurück zum Zitat O'Connell MB, Madden DM, Murray AM, et al.: Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005, 118:778–781.CrossRefPubMed O'Connell MB, Madden DM, Murray AM, et al.: Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005, 118:778–781.CrossRefPubMed
36.
Zurück zum Zitat Sipponen P, Harkonen M: Hypochlorhydric stomach: a risk condition for calcium malabsorption and osteoporosis? Scand J Gastroenterol 2010, 45:133–138.CrossRefPubMed Sipponen P, Harkonen M: Hypochlorhydric stomach: a risk condition for calcium malabsorption and osteoporosis? Scand J Gastroenterol 2010, 45:133–138.CrossRefPubMed
37.
Zurück zum Zitat Yu EW, Blackwell T, Ensrud KE, et al.: Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008, 83:251–259.CrossRefPubMed Yu EW, Blackwell T, Ensrud KE, et al.: Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008, 83:251–259.CrossRefPubMed
38.
Zurück zum Zitat Wright MJ, Sullivan RR, Gaffney-Stomberg E, et al.: Inhibiting gastric acid production does not affect intestinal calcium absorption in young healthy individuals: a randomized, crossover controlled clinical trial. J Bone Miner Res 2010 (Epub ahead of print). Wright MJ, Sullivan RR, Gaffney-Stomberg E, et al.: Inhibiting gastric acid production does not affect intestinal calcium absorption in young healthy individuals: a randomized, crossover controlled clinical trial. J Bone Miner Res 2010 (Epub ahead of print).
39.
Zurück zum Zitat Wright MJ, Proctor DD, Insogna KL, Kerstetter JE: Proton pump-inhibiting drugs, calcium homeostasis, and bone health. Nutr Rev 2008, 66:103–108.CrossRefPubMed Wright MJ, Proctor DD, Insogna KL, Kerstetter JE: Proton pump-inhibiting drugs, calcium homeostasis, and bone health. Nutr Rev 2008, 66:103–108.CrossRefPubMed
40.
Zurück zum Zitat Tuukkanen J, Vaananen HK: Omeprazole, a specific inhibitor of H + -K + -ATPase, inhibits bone resorption in vitro. Calcif Tissue Int 1986, 38:123–125.CrossRefPubMed Tuukkanen J, Vaananen HK: Omeprazole, a specific inhibitor of H + -K + -ATPase, inhibits bone resorption in vitro. Calcif Tissue Int 1986, 38:123–125.CrossRefPubMed
41.
Zurück zum Zitat Sheraly AR, Lickorish D, Sarraf F, Davies JE: Use of gastrointestinal proton pump inhibitors to regulate osteoclast-mediated resorption of calcium phosphate cements in vivo. Curr Drug Deliv 2009, 6:192–198.CrossRefPubMed Sheraly AR, Lickorish D, Sarraf F, Davies JE: Use of gastrointestinal proton pump inhibitors to regulate osteoclast-mediated resorption of calcium phosphate cements in vivo. Curr Drug Deliv 2009, 6:192–198.CrossRefPubMed
42.
43.
Zurück zum Zitat Johnson DA: Safety of proton pump inhibitors: current evidence for osteoporosis and interaction with antiplatelet agents. Curr Gastroenterol Rep 2010, 12:167–174.CrossRefPubMed Johnson DA: Safety of proton pump inhibitors: current evidence for osteoporosis and interaction with antiplatelet agents. Curr Gastroenterol Rep 2010, 12:167–174.CrossRefPubMed
44.
Zurück zum Zitat Cote GA, Howden CW: Potential adverse effects of proton pump inhibitors. Curr Gastroenterol Rep 2008, 10:208–214.CrossRefPubMed Cote GA, Howden CW: Potential adverse effects of proton pump inhibitors. Curr Gastroenterol Rep 2008, 10:208–214.CrossRefPubMed
45.
46.
Zurück zum Zitat Moayyedi P, CAG Clinical Affairs Committee: Hip fracture and proton pump inhibitor therapy: position statement. Can J Gastroenterol 2008, 22:855–858.PubMed Moayyedi P, CAG Clinical Affairs Committee: Hip fracture and proton pump inhibitor therapy: position statement. Can J Gastroenterol 2008, 22:855–858.PubMed
47.
Zurück zum Zitat Corley DA: Proton pump inhibitor, H2 antagonists, and risk of hip fracture: a large population-based study [abstract]. Gastroenterology 2009, 136:A70.CrossRef Corley DA: Proton pump inhibitor, H2 antagonists, and risk of hip fracture: a large population-based study [abstract]. Gastroenterology 2009, 136:A70.CrossRef
48.
Zurück zum Zitat •• Roux C, Briot K, Gossec L, et al.: Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 2009, 84:13–19. This article describes the only prospective study examining the effects of chronic PPI use on bone fractures, demonstrating a threefold increase in risk of vertebral fractures with chronic PPI use in postmenopausal females. •• Roux C, Briot K, Gossec L, et al.: Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 2009, 84:13–19. This article describes the only prospective study examining the effects of chronic PPI use on bone fractures, demonstrating a threefold increase in risk of vertebral fractures with chronic PPI use in postmenopausal females.
49.
Zurück zum Zitat Targownik LE, Lix LM, Metge CJ, et al.: Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008, 179:319–326.PubMed Targownik LE, Lix LM, Metge CJ, et al.: Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008, 179:319–326.PubMed
51.
Zurück zum Zitat Graziani G, Como G, Badalamenti S, et al.: Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dial Transplant 1995, 10:1376–1380.PubMed Graziani G, Como G, Badalamenti S, et al.: Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dial Transplant 1995, 10:1376–1380.PubMed
52.
Zurück zum Zitat Bo-Linn GW, Davis GR, Buddrus DJ, et al.: An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest 1984, 73:640–647.CrossRefPubMed Bo-Linn GW, Davis GR, Buddrus DJ, et al.: An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest 1984, 73:640–647.CrossRefPubMed
53.
Zurück zum Zitat Serfaty-Lacrosniere C, Wood RJ, Voytko D, et al.: Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr 1995, 14:364–368.PubMed Serfaty-Lacrosniere C, Wood RJ, Voytko D, et al.: Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr 1995, 14:364–368.PubMed
54.
Zurück zum Zitat Knox TA, Kassarjian Z, Dawson-Hughes B, et al.: Calcium absorption in elderly subjects on high- and low-fiber diets: effect of gastric acidity. Am J Clin Nutr 1991, 53:1480–1486.PubMed Knox TA, Kassarjian Z, Dawson-Hughes B, et al.: Calcium absorption in elderly subjects on high- and low-fiber diets: effect of gastric acidity. Am J Clin Nutr 1991, 53:1480–1486.PubMed
55.
Zurück zum Zitat Heaney RP, Smith KT, Recker RR, Hinders SM: Meal effects on calcium absorption. Am J Clin Nutr 1989, 49:372–376.PubMed Heaney RP, Smith KT, Recker RR, Hinders SM: Meal effects on calcium absorption. Am J Clin Nutr 1989, 49:372–376.PubMed
56.
Zurück zum Zitat Mizunashi K, Furukawa Y, Katano K, Abe K: Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 1993, 53:21–25.CrossRefPubMed Mizunashi K, Furukawa Y, Katano K, Abe K: Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 1993, 53:21–25.CrossRefPubMed
57.
Zurück zum Zitat Cui GL, Syversen U, Zhao CM, et al.: Long-term omeprazole treatment suppresses body weight gain and bone mineralization in young male rats. Scand J Gastroenterol 2001, 36:1011–1015.CrossRefPubMed Cui GL, Syversen U, Zhao CM, et al.: Long-term omeprazole treatment suppresses body weight gain and bone mineralization in young male rats. Scand J Gastroenterol 2001, 36:1011–1015.CrossRefPubMed
58.
Zurück zum Zitat Tolia V, Boyer K: Long-term proton pump inhibitor use in children: a retrospective review of safety. Dig Dis Sci 2008, 53:385–393.CrossRefPubMed Tolia V, Boyer K: Long-term proton pump inhibitor use in children: a retrospective review of safety. Dig Dis Sci 2008, 53:385–393.CrossRefPubMed
59.
Zurück zum Zitat Tucker KL, Hannan MT, Qiao N, et al.: Low plasma vitamin B12 is associated with lower BMD: the Framingham Osteoporosis Study. J Bone Miner Res 2005, 20:152–158.CrossRefPubMed Tucker KL, Hannan MT, Qiao N, et al.: Low plasma vitamin B12 is associated with lower BMD: the Framingham Osteoporosis Study. J Bone Miner Res 2005, 20:152–158.CrossRefPubMed
60.
Zurück zum Zitat Morris MS, Jacques PF, Selhub J: Relation between homocysteine and B-vitamin status indicators and bone mineral density in older Americans. Bone 2005, 37:234–242.CrossRefPubMed Morris MS, Jacques PF, Selhub J: Relation between homocysteine and B-vitamin status indicators and bone mineral density in older Americans. Bone 2005, 37:234–242.CrossRefPubMed
61.
Zurück zum Zitat Miret S, Simpson RJ, McKie AT: Physiology and molecular biology of dietary iron absorption. Annu Rev Nutr 2003, 23:283–301.CrossRefPubMed Miret S, Simpson RJ, McKie AT: Physiology and molecular biology of dietary iron absorption. Annu Rev Nutr 2003, 23:283–301.CrossRefPubMed
62.
Zurück zum Zitat Koop H, Bachem MG: Serum iron, ferritin, and vitamin B 12 during prolonged omeprazole therapy. J Clin Gastroenterol 1992, 14:288–292.CrossRefPubMed Koop H, Bachem MG: Serum iron, ferritin, and vitamin B 12 during prolonged omeprazole therapy. J Clin Gastroenterol 1992, 14:288–292.CrossRefPubMed
63.
Zurück zum Zitat • Hutchinson C, Geissler CA, Powell JJ, Bomford A: Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 2007, 56:1291–1295. This article describes a well-done recent study demonstrating that PPIs can decrease the absorption of iron in patients with primary hemochromatosis and that its chronic use can decrease the frequency of phlebotomies needed to maintain body iron stores at correct levels.CrossRefPubMed • Hutchinson C, Geissler CA, Powell JJ, Bomford A: Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 2007, 56:1291–1295. This article describes a well-done recent study demonstrating that PPIs can decrease the absorption of iron in patients with primary hemochromatosis and that its chronic use can decrease the frequency of phlebotomies needed to maintain body iron stores at correct levels.CrossRefPubMed
64.
Zurück zum Zitat Epstein M, McGrath S, Law F: Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 2006, 355:1834–1836.CrossRefPubMed Epstein M, McGrath S, Law F: Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 2006, 355:1834–1836.CrossRefPubMed
65.
Zurück zum Zitat Cundy T, Dissanayake A: Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf) 2008, 69:338–341.CrossRef Cundy T, Dissanayake A: Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf) 2008, 69:338–341.CrossRef
66.
Zurück zum Zitat Kuipers MT, Thang HD, Arntzenius AB: Hypomagnesaemia due to use of proton pump inhibitors—a review. Neth J Med 2009, 67:169–172.PubMed Kuipers MT, Thang HD, Arntzenius AB: Hypomagnesaemia due to use of proton pump inhibitors—a review. Neth J Med 2009, 67:169–172.PubMed
67.
Zurück zum Zitat Shabajee N, Lamb EJ, Sturgess I, Sumathipala RW: Omeprazole and refractory hypomagnesaemia. BMJ 2008, 337:a425.CrossRefPubMed Shabajee N, Lamb EJ, Sturgess I, Sumathipala RW: Omeprazole and refractory hypomagnesaemia. BMJ 2008, 337:a425.CrossRefPubMed
68.
Zurück zum Zitat • Mackay JD, Bladon PT: Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. QJM 2010, 103:387–395. This recent report of the characteristics of 10 cases of PPI-induced hypomagnesemia emphasizes its refractory nature, severity of manifestations, and disappearance when the PPI is stopped.CrossRefPubMed • Mackay JD, Bladon PT: Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. QJM 2010, 103:387–395. This recent report of the characteristics of 10 cases of PPI-induced hypomagnesemia emphasizes its refractory nature, severity of manifestations, and disappearance when the PPI is stopped.CrossRefPubMed
69.
Zurück zum Zitat Hoorn EJ , van der Hoek J, de Man RA, et al.: A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 2010, 56:112–116.CrossRefPubMed Hoorn EJ , van der Hoek J, de Man RA, et al.: A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 2010, 56:112–116.CrossRefPubMed
70.
Zurück zum Zitat Francois M, Lévy-Bohbot N, Caron J, Durlach V: Chronic use of proton-pump inhibitors associated with giardiasis: a rare cause of hypomagnesemic hypoparathyroidism? [in French]. Ann Endocrinol (Paris) 2008, 69:446–448. Francois M, Lévy-Bohbot N, Caron J, Durlach V: Chronic use of proton-pump inhibitors associated with giardiasis: a rare cause of hypomagnesemic hypoparathyroidism? [in French]. Ann Endocrinol (Paris) 2008, 69:446–448.
71.
Zurück zum Zitat Broeren MA, Geerdink EA, Vader HL, van den Wall Bake AW: Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med 2009, 151:755–756.PubMed Broeren MA, Geerdink EA, Vader HL, van den Wall Bake AW: Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med 2009, 151:755–756.PubMed
Metadaten
Titel
Association of Long-Term Proton Pump Inhibitor Therapy with Bone Fractures and Effects on Absorption of Calcium, Vitamin B12, Iron, and Magnesium
verfasst von
Tetsuhide Ito
Robert T. Jensen
Publikationsdatum
01.12.2010
Verlag
Current Science Inc.
Erschienen in
Current Gastroenterology Reports / Ausgabe 6/2010
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-010-0141-0

Weitere Artikel der Ausgabe 6/2010

Current Gastroenterology Reports 6/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.